Skip to main content

Ipsogen Licenses Mutation from French Institutes for Myeloproliferative Disorders

NEW YORK, March 30 (GenomeWeb News) - Ipsogen has obtained an exclusive worldwide license from three French institutions to a mutation in the JAK2 gene believed to enable researchers to better classify myeloproliferative disorders, the company said today.

 

It licensed the mutated tyrosine kinase from the Institut Gustave Roussy, the French National Health and Medical Research Institute, and Assistance Publique-Hôpitaux de Paris.

 

If used as a biomarker, the mutation can provide information about the nature of an elevated platelet or red blood cell count, which occurs frequently. Ipsogen said it is developing a "decentralized" CE marked test that will integrate the company's FusionQuant and ProfileQuant technologies.

 

Financial terms of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.